Enhanced antitumor efficacy of oncolytic HSV1, G47delta
| Project/Area Number |
15K10328
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
Tanaka Minoru 東京大学, 医科学研究所, 特任准教授 (50332581)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
稲生 靖 東京大学, 医科学研究所, 准教授 (50372371)
藤堂 具紀 東京大学, 医科学研究所, 教授 (80272566)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | ウイルス療法 / がん治療用ウイルス / 口唇ヘルペス / G47Δ / 抗腫瘍免疫 / ウイル療法 / がん治療ウイルス / HSV-1 |
|---|
| Outline of Final Research Achievements |
The viral therapy is a new treatment of enhanced tumor-selective viral replication and cell killing. G47Δ is a third-generation oncolytic herpes simplex virus type 1 (HSV-1) that has triple mutations created in the HSV-1 genome. G47Δ can actually induce systemic antitumor immunity by activating natural killer cells and Th1 cells. We believe G47Δ will become a standard treatment for malignant tumors.
|
Report
(4 results)
Research Products
(13 results)
-
-
-
[Journal Article] Improved preservation of function during acoustic neuroma surgery2015
Author(s)
Nakatomi H, Miyazaki H, Tanaka M, Kin T, Yoshino M, Oyama H, Usui M, Moriyama H, Kojima H, Kaga K, Saito N
-
Journal Title
J Neurosurge.
Volume: 122
Issue: 1
Pages: 24-33
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
[Book] 実験医学2016
Author(s)
田中実、岩井美和子、藤堂具紀
Total Pages
4
Publisher
羊土社
Related Report
-
-
-
